Literature DB >> 9178476

Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.

C J Luke1, R C Huebner, V Kasmiersky, A G Barbour.   

Abstract

The lipoprotein outer surface protein A (OspA) of the Lyme disease agent. Borrelia burgdorferi, has provided protection to mice and other animals against systemic infection when delivered orally as a recombinant protein in Escherichia coli, bacille Calmette. Guerin or Salmonella typhimurium. In the present study purified recombinant strain B31 OspA or outer surface protein D (OspD), another lipoprotein of B. burgdorferi, were administered either subcutaneously (s.c.) or orally without cell carrier or adjuvant to mice. In comparison to the OspD preparation, the OspA protein was 256-fold more resistant to trypsin. Whereas OspA in the suspension was in regular complexes of 17-25 nm in size, OspD formed amorphous globules of different sizes. Animals received a primary immunization and at least one booster. Mice immunized s.c. with either OspA or OspD had detectable antibodies to B. burgdorferi by enzyme-linked immunosorbent assay (ELISA), growth inhibition assay (GIA) and immunoblot. Delivered orally, OspA but not OspD elicited a specific antibody response, including IgA, as determined by these assays. The geometric mean titre of sera from mice who received 4 micrograms of OspA orally on days 1, 2, 4, 21 and 22 was 1470 by Ig ELISA, 320 by IgA ELISA and 128 by GIA. In infectious challenge experiments with B. burgdorferi strain Sh2-2-82 (OspA+ OspD- ) inoculated intradermally at 100 x the ID 50 all eight mice immunized with the 4 micrograms dose of OspA were protected, none of the mice immunized with the 4 micrograms dose of OspD were protected (P < 0.001 by Fisher exact test). These studies indicate that the lipoprotein OspA provides protection against systemic B. burgdorferi infection when delivered orally as a purified protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178476     DOI: 10.1016/s0264-410x(97)00219-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease.

Authors:  Debaditya Bhattacharya; Mekki Bensaci; Kathryn E Luker; Gary Luker; Steven Wisdom; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

Review 2.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

4.  Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.

Authors:  Luciana Meirelles Richer; Miguel Aroso; Tania Contente-Cuomo; Larisa Ivanova; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

5.  Access of antibody or trypsin to an integral outer membrane protein (P66) of Borrelia burgdorferi is hindered by Osp lipoproteins.

Authors:  J Bunikis; A G Barbour
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle.

Authors:  Jean I Tsao; J Timothy Wootton; Jonas Bunikis; Maria Gabriela Luna; Durland Fish; Alan G Barbour
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

7.  Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.

Authors:  Maarten J Voordouw; Haley Tupper; Özlem Önder; Godefroy Devevey; Christopher J Graves; Brian D Kemps; Dustin Brisson
Journal:  Vector Borne Zoonotic Dis       Date:  2013-02-21       Impact factor: 2.133

8.  Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease.

Authors:  Beatriz del Rio; Raymond J Dattwyler; Miguel Aroso; Vera Neves; Luciana Meirelles; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

9.  Role of outer surface protein D in the Borrelia burgdorferi life cycle.

Authors:  Xin Li; Girish Neelakanta; Xianzhong Liu; Deborah S Beck; Fred S Kantor; Durland Fish; John F Anderson; Erol Fikrig
Journal:  Infect Immun       Date:  2007-07-09       Impact factor: 3.441

Review 10.  Blocking pathogen transmission at the source: reservoir targeted OspA-based vaccines against Borrelia burgdorferi.

Authors:  Maria Gomes-Solecki
Journal:  Front Cell Infect Microbiol       Date:  2014-09-26       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.